The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

被引:15
|
作者
Rosende-Roca, Maitee [1 ,2 ]
Abdelnour, Carla [1 ,2 ,3 ]
Esteban, Ester [1 ,2 ]
Tartari, Juan Pablo [1 ,2 ]
Alarcon, Emilio [1 ,2 ]
Martinez-Atienza, Juliana [1 ,2 ]
Gonzalez-Perez, Antonio [1 ,2 ]
Saez, Maria E. [1 ,2 ]
Lafuente, Asuncion [1 ,2 ]
Buendia, Mar [1 ,2 ]
Pancho, Ana [1 ,2 ]
Aguilera, Nuria [1 ,2 ]
Ibarria, Marta [1 ,2 ]
Diego, Susana [1 ,2 ]
Jofresa, Sara [1 ,2 ]
Hernandez, Isabel [1 ,2 ,3 ]
Lopez, Rogelio [1 ,2 ]
Gurruchaga, Miren Jone [1 ,2 ]
Tarraga, Lluis [1 ,2 ,3 ]
Valero, Sergi [1 ,2 ,3 ]
Ruiz, Agustin [1 ,2 ,3 ]
Marquie, Marta [1 ,2 ,3 ]
Boada, Merce [1 ,2 ,3 ]
机构
[1] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Res Ctr, Gran Via Carles III,85 BIS, Barcelona 08028, Spain
[2] Univ Int Catalunya, Fundacio ACE, Inst Catala Neurociencies Aplicades, Memory Clin, Gran Via Carles III,85 BIS, Barcelona 08028, Spain
[3] Inst Salud Carlos III, Networking Res Ctr Neurodegenerat Dis CIBERNED, Madrid, Spain
关键词
Alzheimer's disease; Dementia; Mild cognitive impairment; Sex; Gender; Women; Aging; Education; Elderly; MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DISEASE; DEMENTIA; OLDER; RISK; RECOMMENDATIONS; EPIDEMIOLOGY;
D O I
10.1186/s13195-021-00833-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis, biomarker status, and risk factors. Despite this, the interaction of sex has received limited attention, with AD trials persistently recruiting lower numbers of women than the population distribution and a lack of information on the sex-disaggregated effects of anti-dementia therapies. This is the first study aiming to identify the role of sex in the selection for screening in AD clinical trials. Methods This cross-sectional study provides a comprehensive analysis of screening eligibility according to a set of pre-selection criteria currently applied at Fundacio ACE memory clinic for a more efficient trial screening process. A cohort of 6667 women and 2926 men diagnosed with AD dementia (55%) or mild cognitive impairment (45%) was analyzed. We also assessed the frequencies of men and women effectively screened for trial enrolment over a period of 10 years. Additionally, data from AddNeuroMed study was used to explore trends in eligibility based on the education criteria. Results Women showed a significantly lower chance of being eligible for screening than men (OR = 1.26; p < 0.01). This imbalance was confirmed by a lower frequency of women screened for enrolment compared to the study population (63.0% vs. 69.5%). Education was revealed as the key criterion contributing to this unbalance, with men showing over twice the chance of being screened compared with women (OR = 2.25, p < 0.01). Education-based differences were greater in earlier born patients, but the gap narrowed and achieved balance with increasing year of birth. This observation was replicated using data from other European populations included in AddNeuroMed study. Comorbidity was the most limiting criterion with sex differences in frequencies and significant discrimination against the selection of men (OR = 0.86, p < 0.01). Conclusions The large number of low-educated elderly women with AD demands for a sex-focused approach in clinical research. New assessment tools insensitive to education level should be developed to enable a proportional representation of women. Although this gender education gap is mostly inexistent in developed countries, economic or cultural factors may lead to different scenarios in other regions. Overlooking the impact of sex may lead to a handicap in AD research with a direct adverse impact on women's health.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
    Maitee Rosende-Roca
    Carla Abdelnour
    Ester Esteban
    Juan Pablo Tartari
    Emilio Alarcon
    Juliana Martínez-Atienza
    Antonio González-Pérez
    María E. Sáez
    Asunción Lafuente
    Mar Buendía
    Ana Pancho
    Nuria Aguilera
    Marta Ibarria
    Susana Diego
    Sara Jofresa
    Isabel Hernández
    Rogelio López
    Miren Jone Gurruchaga
    Lluís Tárraga
    Sergi Valero
    Agustín Ruiz
    Marta Marquié
    Mercè Boada
    Alzheimer's Research & Therapy, 13
  • [2] Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences
    Mielke, Michelle M.
    Vemuri, Prashanthi
    Rocca, Walter A.
    CLINICAL EPIDEMIOLOGY, 2014, 6 : 37 - 48
  • [3] The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
    Rios-Romenets, S.
    Giraldo-Chica, M.
    Lopez, H.
    Piedrahita, F.
    Ramos, C.
    Acosta-Baena, N.
    Munoz, C.
    Ospina, P.
    Tobon, C.
    Cho, W.
    Ward, M.
    Langbaum, B.
    Tariot, P. N.
    Reiman, E. M.
    Lopera, F.
    JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (01): : 49 - 54
  • [4] Sex/gender differences in the clinical trajectory of Alzheimer's disease: Insights into diagnosis and cognitive reserve
    Emrani, Sheina
    Sundermann, Erin E.
    FRONTIERS IN NEUROENDOCRINOLOGY, 2025, 77
  • [5] Race- and Sex-Based Disparities in Alzheimer's Disease Clinical Trial Enrollment in the United States and Canada: An Indigenous Perspective
    Olson, Nancy L.
    Albensi, Benedict C.
    JOURNAL OF ALZHEIMERS DISEASE REPORTS, 2020, 4 (01) : 325 - 344
  • [6] Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project
    Boada, Merce
    Rodrigo, Adrian
    Jessen, Frank
    Wimblad, Bengt
    Kramberger, Milika
    Visser, Pieter Jelle
    Simo, Rafael
    Rodriguez-Gomez, Octavio
    Ciudin, Andreea
    Georges, Jean
    Dumas, Annete
    Maguire, Peggy
    Krivec, David
    Wimo, Anders
    Valero, Sergi
    Alegret, Montserrat
    Jamilis, Laura
    Zwan, Marissa
    Sannemann, Lena
    Arrufat, Jordi
    Stomrud, Erik
    Johansson, Gunilla
    Shering, Craig
    Glaysher, Bridget
    Stewart, Neil
    Belger, Mark
    Iradier, Fatima
    Campo, Laura
    ALZHEIMERS & DEMENTIA, 2022, 18 (06) : 1119 - 1127
  • [7] Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
    Cullen, Nicholas C.
    Janelidze, Shorena
    Stomrud, Erik
    Bateman, Randall J.
    Palmqvist, Sebastian
    Hansson, Oskar
    Mattsson-Carlgren, Niklas
    BRAIN COMMUNICATIONS, 2023, 5 (02)
  • [8] Activity level by clinical severity and sex differences in patients with Alzheimer disease and mild cognitive impairment
    Kamizato, Chiaki
    Osawa, Aiko
    Maeshima, Shinichiro
    Kagaya, Hitoshi
    Arai, Hidenori
    PSYCHOGERIATRICS, 2023, 23 (05) : 815 - 820
  • [9] Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease
    Lin, Szu-Ying
    Lin, Kun-Ju
    Lin, Po-Chen
    Huang, Chin-Chang
    Chang, Chiung-Chih
    Lee, Yi-Chung
    Hsiao, Ing-Tsung
    Yen, Tzu-Chen
    Huang, Wen-Sheng
    Yang, Bang-Hung
    Wang, Pei-Ning
    ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (01)
  • [10] Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease The ADMET 2 Randomized Clinical Trial
    Mintzer, Jacobo
    Lanctot, Krista L.
    Scherer, Roberta W.
    Rosenberg, Paul B.
    Herrmann, Nathan
    van Dyck, Christopher H.
    Padala, Prasad R.
    Brawman-Mintzer, Olga
    Porsteinsson, Anton P.
    Lerner, Alan J.
    Craft, Suzanne
    Levey, Allan, I
    Burke, William
    Perin, Jamie
    Shade, David
    JAMA NEUROLOGY, 2021, 78 (11) : 1324 - 1332